Capstone Therapeutics Corp（以下简称“Capstone”）近日发布投资者问答文件，披露公司已成功将可转换债券本金规模削减72%。这一重大财务举措显著优化了公司资本结构，同时管理层重申对2026财年的业绩指引保持稳定。
此次可转换债券本金的大幅削减，体现了Capstone积极管理债务水平的战略决心。通过降低负债规模，公司不仅减轻了利息支出压力，更为未来业务拓展创造了更灵活的财务空间。投资者问答文件还详细说明了债务重组的具体条款及其对财务指标的预期影响。
尽管面临市场波动，Capstone仍坚持对2026财年的业绩展望。公司强调，核心业务板块增长动能充足，现金流状况持续改善，现有订单规模为达成年度目标提供有力支撑。管理层表示，将通过精细化运营和战略聚焦，确保实现既定财务指标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.